Mammoth Biosciences Stock: The Next CRISPR IPO?
CRISPR is an exciting technology that enables a new class of diagnostic tests and therapies for congenital diseases. Mammoth Biosciences is a leading private company in the space.
Biotech
Neuralink Stock: Will Neuralink IPO Next Year?
Neuralink is Elon Musk’s attempt to bridge the gap between the digital world and the human brain. The medical applications of a brain-machine interface could improve the lives of millions. Though Musk’s ultimate goal is to merge AI and I.
eGenesis Stock: Enabling Pig-to-Human Organ Transplants
eGenesis has developed a gene editing process to make pig organs transplantable into humans. CRISPR has the potential to reduce immune reject, thus creating a long-term solution to the global organ donor shortage.
Synchron Stock, Valuation, and IPO Potential
Thanks to its wealthy founder, Neuralink gets most of the brain-computer interface (BCI) news coverage. But an Australian/U.S.-based company is further along the FDA approval process, and its device is less intrusive than its competitors.
Freenome Stock: Will Freenome IPO in the Next Few Years?
Freenome is on a mission to detect cancer early to aid in doctors’ ability to treat it and save lives. Retail investors own this innovative startup today, potentially years before an acquisition or public offering.
Colossal Biosciences Stock: Will Colossal IPO or Go Extinct?
Colossal Biosciences aims to leverage genomics technology and advanced sciences to bring back animals like the woolly mammoth and the dodo bird from extinction. But is there a viable business model?